<DOC>
	<DOCNO>NCT00038883</DOCNO>
	<brief_summary>High dose chemotherapy follow transplantation allogeneic hematopoietic stem cell use Campath-1h , monoclonal antibody synergistic effect chemotherapy minimal toxicity . In addition Campath-1H improve engraftment donor cell immunosuppressive property .</brief_summary>
	<brief_title>Campath-1H Allogeneic Blood Stem Cell Transplantation Lymphoid Malignancies</brief_title>
	<detailed_description>Alemtuzumab drug design specifically attack type leukemia lymphoma cell . In addition , weaken immune system , help prevent rejection donor marrow stem cell . If find eligible take part study , admit hospital treatment . Alemtuzumab inject vein period 4 hour . This do 5 day row ( Days 1 5 ) . Drugs diphenhydramine ( Benadryl ) , solumedrol acetaminophen ( Tylenol ) give decrease risk ease side effect dose alemtuzumab . You also receive Carmustine one hour first day . From second fifth day , receive cytarabine etoposide twice day . On six day , receive melphalan . Both drug give catheter ( plastic tube ) extend large chest vein . The catheter leave place throughout treatment study . Some participant , depend type disease , also receive rituximab . Rituximab give first day chemotherapy week total 4 dos . When chemotherapy finish , blood stem cell donor give catheter . G-CSF , growth factor promote production blood cell , injected skin day blood cell count recover certain level . Blood test ( 2 tablespoon ) , urine test , bone marrow aspiration , x-rays do need track effect transplant . The blood test draw daily hospital least twice weekly outpatient first 100 day . The CT scan bone marrow study do 1 , 3 , 6 , 12 month every 6 month least 3 year transplant . You may also transfusions blood platelet need . You need stay hospital 3 4 week . You take study disease get bad intolerable side effect occur . You must stay Houston area 100 day transplant . After , ask return Houston every 6 month next 3-5 year scan ( CT , gallium , PET scan ) , bone marrow aspiration next 3-5 year . This investigational study . The FDA approve drug use study . Their use together study investigational . About 142 patient take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Alemtuzumab</mesh_term>
	<criteria>1 . 1565 year old 2 . B Tcell lymphoid disease , eligible nonmyeloablative transplantation . 3 . Patients relapse fail conventional chemotherapy . 4 . Patients HLAidentical oneantigen mismatch sibling , match unrelated donor . 5 . Performance status &lt; /=2 . 1 . Past history anaphylaxis follow exposure rat mouse derive CDRgrafted humanize monoclonal antibody . 2 . Less 4 week since prior chemotherapy . 3 . Pregnancy lactation . 4 . HIV HTLVI positivity . 5 . Serum creatinine &gt; 1.6 mg/dl serum bilirubin &gt; 0.2 mg/dl unless due tumor , SGPT &gt; /= 2 x NI 6 . PFTDCLO &lt; 50 % , cardiac EF &lt; 50 % predicted level .</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>Lymphoid Malignancies</keyword>
	<keyword>Chronic Lymphocytic Leukemia</keyword>
	<keyword>Acute Lymphoblastic Leukemia</keyword>
	<keyword>Low grade Lymphoma</keyword>
	<keyword>B T cell Lymphoma intermediate high grade</keyword>
</DOC>